Analyst Consensus ?
ConsensusHold28 ratings
Bullish828.6%
Neutral1657.1%
Bearish414.3%
GSK plc · GSK · FY2025 Q3 · Calendar Q4 2025
GSK’s specialty-medicine growth supports a higher 2025 outlook
The call analysis presents specialty medicines—particularly oncology, immunology and HIV—as the central growth engine, with management raising its 2025 outlook and describing a broad late-stage pipeline. The investment case described by management depends on converting launches and pipeline programs into sustained growth; access, policy and execution concerns remain relevant counterweights.
Reported Before market openNYSEHealthcare
$98.71B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$1.48
Consensus $1.26
EPS surprise
+17.5%
Reported versus consensus
Reported revenue
$11.32B
Consensus $11.04B
Revenue surprise
+2.6%
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
+5.1%
Event window
SPY move
+0.0%
Same window
Abnormal move
+5.1%
Stock minus SPY
Volume
2.3×
Versus trailing sessions
Subsequent drift
+4.6%
Up to 20 sessions
GSKSPY benchmark
Ask FN2 about GSK FY2025 Q3
Transcript, numbers and history already loaded
Why did GSK rise 5.1% after beating EPS estimates in FY2025 Q3?What changed in GSK's guidance and outlook in FY2025 Q3?Give me the bull and bear case for GSK after FY2025 Q3 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior-quarter analysis, which said full-year guidance had been raised to the top end of its range, the Q3 call analysis reports a further upgrade to the 2025 sales-growth and operating-profit-growth outlook. The update also emphasizes BLENREP’s US launch, depemokimab’s pending decision and advancement of multiple scale opportunities.
Guidance delta
Raised 2025 guidance to 6–7% sales growth and 9–11% operating-profit growth, according to the supplied transcript analysis. The prior-quarter analysis had described guidance as raised to the top end of the range.
Key takeaways
- Specialty medicines, including oncology and HIV, were identified as the primary growth engine.
- The analysis reports Q3 sales and earnings above expectations, with sales up 8% and EPS up 14%.
- Management highlighted BLENREP’s US launch and upcoming product launches, including depemokimab subject to regulatory review.
- The pipeline and continued R&D investment were presented as supports for longer-term growth; successful development and commercialization remain execution-dependent.
Management priorities
- Launch BLENREP and advance its expanded indications.
- Progress depemokimab and other late-stage pipeline programs through regulatory and clinical milestones.
- Advance the HIV pipeline and product launches, including long-acting regimens.
- Continue research investment, business development and manufacturing capacity expansion.
Follow GSK with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$49.27Current
$35.25Low
$48.86Average
$60High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 3, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Jefferies | Hold | Buy | Downgrade | Oct 29, 2026 |
| Barclays | Underweight | Equal Weight | Downgrade | Jan 6, 2026 |
| Guggenheim | Neutral | Buy | Downgrade | Oct 31, 2024 |
| UBS | Neutral | Buy | Downgrade | Jul 8, 2024 |
| DZ Bank | Hold | Buy | Downgrade | Feb 11, 2022 |
| SVB Leerink | Market Perform | Outperform | Downgrade | Mar 23, 2021 |
| Deutsche Bank | Sell | Hold | Downgrade | Feb 4, 2021 |
| Argus Research | Buy | Buy | Maintain | Nov 11, 2019 |
| New Street | Hold | Reduce | Upgrade | Oct 16, 2019 |
| Cantor Fitzgerald | Buy | Hold | Upgrade | Oct 11, 2019 |
| Societe Generale | Buy | Sell | Upgrade | Sep 3, 2019 |
| Exane BNP Paribas | Neutral | Outperform | Downgrade | Jan 14, 2019 |
| SunTrust Robinson Humphrey | Hold | Hold | Maintain | Dec 14, 2018 |
| Morgan Stanley | Underweight | Underweight | Maintain | Dec 14, 2018 |
| Argus | Buy | Buy | Maintain | Aug 20, 2018 |
| Bank of America | Neutral | Buy | Downgrade | Oct 26, 2017 |
| Citigroup | Neutral | Buy | Downgrade | Jul 5, 2017 |
| PiperJaffray | Overweight | Overweight | Maintain | Sep 23, 2016 |
| Bryan Garnier | Buy | Neutral | Upgrade | Jan 27, 2016 |
| Credit Suisse | Neutral | Underperform | Upgrade | Oct 20, 2015 |
| JP Morgan | Neutral | Underweight | Upgrade | Oct 12, 2015 |
| Mainfirst | Underperform | Underperform | Maintain | Jul 28, 2014 |
| Panmure | Buy | Hold | Upgrade | Apr 22, 2014 |
| S&P Capital IQ | Hold | Sell | Upgrade | Jan 27, 2014 |
| Berenberg | Hold | Buy | Downgrade | Jan 24, 2014 |
| Cowen & Co. | Market Perform | Outperform | Downgrade | Jan 22, 2014 |
| Liberum | Hold | Underweight | Upgrade | Jun 7, 2013 |
| Kepler Cheuvreux | Buy | Hold | Upgrade | Feb 8, 2013 |
Named analyst price targets
Upside is calculated against the persisted current price $49.27. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Jefferies | Analyst unavailable | $55.9 | $48.74 | +13.5% | Oct 29, 2026 |
| Berenberg Bank | Kerry Holford | $60 | $50.05 | +21.8% | Sep 15, 2026 |
| CFRA | Wan Nurhayati | $53 | $46.67 | +7.6% | Oct 30, 2025 |
| BNP Paribas | Peter Verdult | $35.25 | $35.68 | -28.5% | Apr 15, 2025 |
| Jefferies | Peter Welford | $53 | $38.38 | +7.6% | Jul 2, 2024 |
| Guggenheim | Vamil Divan | $36 | $40.69 | -26.9% | Apr 11, 2024 |
Track every rating change on GSK the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationGSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc. Its primary objective is to prevent and treat illnesses by producing both vaccines and a comprehensive range of specialty and general medicines for markets across the United Kingdom, the United States, and internationally. The company's operations are organized into two key divisions: Commercial Operations and Total R&D. Its extensive vaccine portfolio includes immunizations against shingles, meningitis, respiratory syncytial virus (RSV), seasonal and pandemic influenza, and polio.…
Historical context
All GSK earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| PHG Koninklijke Philips N.V. | FY2026 Q3 · Calendar Q4 2026 | — | +4.8% | Philips Q3: order momentum and margins improve; outlook held |
| VRTX Vertex Pharmaceuticals Incorporated | FY2026 Q3 · Calendar Q4 2026 | -1.2% | -1.0% | Vertex lifts 2026 outlook as CF franchise and newer products support growth |
| JAZZ Jazz Pharmaceuticals plc | FY2026 Q3 · Calendar Q4 2026 | +4.2% | -0.7% | Jazz lifts 2026 revenue outlook as Ziihera launch adds momentum |
| BMRN BioMarin Pharmaceutical Inc. | FY2026 Q3 · Calendar Q4 2026 | +376.0% | -1.8% | BioMarin’s Q3 growth meets a lower full-year outlook |
| IDXX IDEXX Laboratories, Inc. | FY2026 Q3 · Calendar Q4 2026 | +6.2% | +21.8% | IDEXX Raises FY2026 Outlook on Diagnostics and Software Growth |
| NBIX Neurocrine Biosciences, Inc. | FY2026 Q3 · Calendar Q4 2026 | +72.3% | -0.5% | Neurocrine Raises INGREZZA Outlook as Core Products Grow |
Latest beats and misses
Who reports nextBeat on EPS
- TSEMFY2026 Q3 · November 2, 2026+7.5% EPS-6.7% move
- CLXFY2027 Q1 · November 2, 2026+44.9% EPS+2.2% move
- AAPLFY2026 Q4 · November 2, 2026+3.0% EPS-1.8% move
- PLTRFY2026 Q3 · November 2, 2026+8.3% EPS-3.1% move
- ETRFY2026 Q3 · November 2, 2026+14.5% EPS-0.2% move
- OFY2026 Q3 · November 2, 2026+5.7% EPS+1.1% move
Missed on EPS
- VRTXFY2026 Q3 · November 2, 2026-1.2% EPS-1.0% move
- PEGFY2026 Q3 · November 2, 2026-3.4% EPS+0.1% move
- RYAAYFY2027 Q2 · November 2, 2026-0.3% EPS+2.9% move
- GLPIFY2026 Q3 · October 29, 2026-11.5% EPS-1.3% move
- LYBFY2026 Q3 · October 30, 2026-1.2% EPS+5.0% move
- CCJFY2026 Q3 · October 30, 2026-101.4% EPS-7.9% move
Get the GSK recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars · 2026-11-03T14:30:49.910071+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-03T14:30:49.907256+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-11-03. For educational purposes only; not investment advice.